Pablo J Cagnoni sold $2.8M of INCY
President, Global Head of R&D at INCYTE CORP. 23,218 shares at an average of $120.49, traded Sep 15, 2026, filed Sep 17, 2026.
Score components
- +20RolePresident
- +25Trade size$2.8M at market
- +5Share of holdings soldSold 11% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001205703-26-000030, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +2,957 | $61.76 | $183k | 186,157 | 25 d ago |
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +4,551 | $61.18 | $278k | 190,708 | 25 d ago |
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +6,477 | $64.25 | $416k | 197,185 | 25 d ago |
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +9,233 | $71.93 | $664k | 206,418 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -9,233 | $120.50 | $1.1M | 197,185 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -13,985 | $120.49 | $1.7M | 183,200 | 25 d ago |
| Sep 15, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,957 | $0.00 | $0 | 4,225 | 25 d ago |
| Sep 15, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -4,551 | $0.00 | $0 | 4,551 | 25 d ago |
| Sep 15, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -6,477 | $0.00 | $0 | 20,356 | 25 d ago |
| Sep 15, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -9,233 | $0.00 | $0 | 18,466 | 25 d ago |
Related signals
Other insiders at INCYTE CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | INCYTE CORP | Sheila A. Denton EVP & General Counsel | $122k 1,795 shares | -6% | |
| 38Weak | INCYTE CORP | Barry P Flannelly EVP & General Manager US | $1.3M 19,807 shares | -37% | |
| 0Weak | INCYTE CORP | Sheila A. Denton EVP & General Counsel | $42k 599 shares | -2% | |
| 15Weak | INCYTE CORP | Sheila A. Denton EVP & General Counsel | $1.0M 14,069 shares | -35% | |
| 24Weak | INCYTE CORP | Steven H Stein EVP & Chief Medical Officer | $898k 12,352 shares | -16% | |
| 12Weak | INCYTE CORP | Thomas Tray Principal Accounting Officer | $91k 1,300 shares | -5% | |
| 25Weak | INCYTE CORP | Vijay K Iyengar EVP, GMAPPS | $456k 6,043 shares | -16% | |
| 0Weak | INCYTE CORP | Barry P Flannelly EVP & General Manager US | $293k 3,680 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.